ATE432470T1 - Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker - Google Patents

Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker

Info

Publication number: ATE432470T1
Authority: AT; Austria
Prior art keywords: inflammatory bowel; bowel disease; ibd; lactoferrin; endogene
Prior art date: 2000-11-14

Application number

AT01996331T

Other languages

English (en)

Inventor

James Boone

David Lyerly

Tracy Wilkins

Richard Guerrant

Original Assignee

Techlab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-14

Filing date

2001-11-14

Publication date

2009-06-15

2001-11-14 Application filed by Techlab Inc filed Critical Techlab Inc

2009-06-15 Application granted granted Critical

2009-06-15 Publication of ATE432470T1 publication Critical patent/ATE432470T1/de

Links

208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 7
102000010445 Lactoferrin Human genes 0.000 title abstract 7
108010063045 Lactoferrin Proteins 0.000 title abstract 7
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title abstract 7
229940078795 lactoferrin Drugs 0.000 title abstract 7
235000021242 lactoferrin Nutrition 0.000 title abstract 7
238000000034 method Methods 0.000 title abstract 3
238000012544 monitoring process Methods 0.000 title abstract 2
239000003550 marker Substances 0.000 title 1
230000002550 fecal effect Effects 0.000 abstract 3

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT01996331T 2000-11-14 2001-11-14 Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker ATE432470T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24828800P	2000-11-14	2000-11-14
PCT/US2001/045301 WO2002039883A2 (en)	2000-11-14	2001-11-14	Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker

Publications (1)

Publication Number	Publication Date
ATE432470T1 true ATE432470T1 (de)	2009-06-15

Family

ID=22938469

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01996331T ATE432470T1 (de)	2000-11-14	2001-11-14	Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker

Country Status (8)

Country	Link
US (3)	US7192724B2 (de)
EP (2)	EP2071332A1 (de)
AT (1)	ATE432470T1 (de)
AU (3)	AU2002902A (de)
CA (1)	CA2427898C (de)
DE (1)	DE60138829D1 (de)
ES (1)	ES2325059T3 (de)
WO (1)	WO2002039883A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE395596T1 (de) *	2002-10-25	2008-05-15	Techlab Inc	Diagnostisches panel ibd-first chek fur entzundliche darmerkrankung (ibd) und reizkolon
US7759079B2 (en) *	2004-05-13	2010-07-20	Prometheus Laboratories Inc.	Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en)	2004-05-13	2006-07-13	Prometheus Laboratories Inc.	Methods of diagnosing inflammatory bowel disease
US7943328B1 (en)	2006-03-03	2011-05-17	Prometheus Laboratories Inc.	Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en)	2006-08-15	2008-04-10	Prometheus Laboratories Inc.	Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) *	2006-08-15	2010-04-15	Prometheus Laboratories Inc.	Methods for diagnosing irritable bowel syndrome
WO2010056682A2 (en)	2008-11-11	2010-05-20	Prometheus Laboratories Inc.	Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
NZ595471A (en)	2009-04-14	2014-01-31	Nestec Sa	Inflammatory bowel disease prognostics
CA2766157A1 (en)	2009-06-25	2010-12-29	Hua Gong	Methods for diagnosing irritable bowel syndrome
WO2011060098A1 (en)	2009-11-10	2011-05-19	Prometheus Laboratories Inc.	Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
WO2011094027A1 (en)	2010-02-01	2011-08-04	Hlavka Edwin J	Bacteriotherapy for clostridium difficile colitis
ES2380664B2 (es)	2010-10-19	2012-09-13	Certest Biotec, S.L.	Método y dispositivo para el diagnóstico rápido de enfermedades en muestras fecales.
ES2530175T3 (es)	2011-02-17	2015-02-26	Nestec S.A.	Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
US20120276060A1 (en)	2011-04-29	2012-11-01	Techlab, Inc.	Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease
US10295535B2 (en)	2011-04-29	2019-05-21	Techlab, Inc.	Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease
WO2015067913A1 (en)	2013-11-07	2015-05-14	Diagnodus Limited	Biomarkers
WO2012154987A1 (en)	2011-05-10	2012-11-15	Nestec Sa	Methods of disease activity profiling for personalized therapy management
EP2734543B1 (de) *	2011-07-24	2018-10-03	Carmel-Haifa University Economic Corp.	Lactoferrinfragmente und verwendung davon
US20120258477A1 (en) *	2011-07-25	2012-10-11	Northwestern University	Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease
EP2769321B1 (de)	2011-10-21	2016-06-01	Nestec S.A.	Verfahren zur verbesserung der diagnose einer entzündlichen darmerkrankung
WO2013082288A1 (en) *	2011-11-29	2013-06-06	The Regents Of The University Of California	Glucorticoid receptor gene nr3c1 methylation in irritable bowel syndrome and other stress disorders
WO2013132347A2 (en)	2012-03-06	2013-09-12	Calpro As	Improved elisa immunoassay for calprotectin
WO2013132338A2 (en)	2012-03-06	2013-09-12	Calpro As	Competitive immunoassay for calprotectin
CN103575903B (zh) *	2012-08-07	2016-01-20	中国检验检疫科学研究院	一种人乳铁蛋白夹心elisa检测试剂盒及其应用
RU2504779C1 (ru) *	2012-10-08	2014-01-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Минздравсоцразвития России	Способ оценки эффективности лечения больных язвенным колитом
US10383901B2 (en)	2013-06-05	2019-08-20	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en)	2013-06-05	2017-10-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en)	2013-06-05	2016-12-06	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP4234011A3 (de)	2013-06-05	2023-09-20	Rebiotix, Inc.	Mikrobiotawiederherstellungstherapie (mrt), zusammensetzungen und verfahren zur herstellung
US9694039B2 (en)	2013-06-05	2017-07-04	Rebiotix, Inc.	Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN107921072A (zh)	2015-06-09	2018-04-17	雷柏奥提斯有限公司	微生物群恢复治疗（mrt）组合物和制造方法
US10905726B2 (en)	2015-06-09	2021-02-02	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en)	2015-06-09	2020-10-13	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en)	2015-06-09	2020-11-10	Rebiotix, Inc.	Microbiota restoration therapy (MRT) compositions and methods of manufacture
DK3171174T3 (en) *	2015-11-20	2018-01-22	Geroa Diagnostics S L	Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease
CN116973572B (zh) *	2023-06-02	2025-03-07	东南大学附属中大医院	基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444879A (en) *	1981-01-29	1984-04-24	Science Research Center, Inc.	Immunoassay with article having support film and immunological counterpart of analyte
US5124252A (en) *	1989-11-28	1992-06-23	University Of Virginia Alumni Patents Foundation	In vitro test for fecal leukocytes
US5552292A (en)	1993-01-18	1996-09-03	Ikagaku Co., Ltd.	Method of screening for colorectal cancer
US5455160A (en)	1993-05-27	1995-10-03	Fagerhol; Magne K.	Diagnostic test and kit for disease or disorders in the digestive system
US5681699A (en)	1994-02-11	1997-10-28	Cedars-Sinai Medical Center	Methods of diagnosing ulcerative colitis and Crohn's disease
US6174664B1 (en) *	1997-02-05	2001-01-16	University Of Pittsburgh	Screening method for inflammatory diseases using neutrophil defensins and lactoferrin
US6358939B1 (en) *	1999-12-21	2002-03-19	Northern Lights Pharmaceuticals, Llc	Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease

2001
- 2001-11-14 EP EP09002897A patent/EP2071332A1/de not_active Ceased
- 2001-11-14 US US10/002,842 patent/US7192724B2/en not_active Expired - Lifetime
- 2001-11-14 ES ES01996331T patent/ES2325059T3/es not_active Expired - Lifetime
- 2001-11-14 AU AU2002902A patent/AU2002902A/xx active Pending
- 2001-11-14 EP EP01996331A patent/EP1340078B1/de not_active Expired - Lifetime
- 2001-11-14 CA CA2427898A patent/CA2427898C/en not_active Expired - Lifetime
- 2001-11-14 AT AT01996331T patent/ATE432470T1/de not_active IP Right Cessation
- 2001-11-14 WO PCT/US2001/045301 patent/WO2002039883A2/en not_active Ceased
- 2001-11-14 DE DE60138829T patent/DE60138829D1/de not_active Expired - Lifetime
- 2001-11-14 AU AU2002220029A patent/AU2002220029B2/en not_active Expired
2003
- 2003-07-30 US US10/629,975 patent/US7560240B2/en not_active Expired - Lifetime
2007
- 2007-11-15 AU AU2007234504A patent/AU2007234504B2/en not_active Expired
2009
- 2009-06-17 US US12/486,727 patent/US7892762B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20090253155A1 (en)	2009-10-08
AU2007234504B2 (en)	2010-11-18
US7560240B2 (en)	2009-07-14
AU2002220029B2 (en)	2007-09-06
ES2325059T3 (es)	2009-08-25
AU2002902A (en)	2002-05-27
EP1340078B1 (de)	2009-05-27
EP2071332A1 (de)	2009-06-17
CA2427898C (en)	2017-08-15
DE60138829D1 (de)	2009-07-09
WO2002039883A3 (en)	2002-08-08
AU2007234504A1 (en)	2007-12-06
WO2002039883A2 (en)	2002-05-23
US20040033537A1 (en)	2004-02-19
US7892762B2 (en)	2011-02-22
US7192724B2 (en)	2007-03-20
US20020168698A1 (en)	2002-11-14
EP1340078A2 (de)	2003-09-03
EP1340078A4 (de)	2006-07-05
CA2427898A1 (en)	2002-05-23

Legal Events

Date	Code	Title	Description
2009-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60138829D1 (de)	2009-07-09	Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
DE602004022150D1 (de)	2009-09-03	Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
ATE532070T1 (de)	2011-11-15	Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
ATE490466T1 (de)	2010-12-15	Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
ATE361024T1 (de)	2007-05-15	Vorrichtung und verfahren zur bestimmung des analytpegels
ATE420204T1 (de)	2009-01-15	Verfahren zur detektion von erkrankungen
ATE319093T1 (de)	2006-03-15	Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen
DK0943097T3 (da)	2003-11-24	Fremgangsmåde til at påvise IgE
DE602005024810D1 (de)	2010-12-30	Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung
DE602004026910D1 (de)	2010-06-10	Faseroptische vorrichtung zur wahrnehmung von analyten
ATE251222T1 (de)	2003-10-15	Verfahren zur bestimung von ki-ras mutationen und dieses leistender testsatz
ATE539675T1 (de)	2012-01-15	System und verfahren zur bestimmung einer analytenkonzentration mit einer hämatokrit- korrektur
ATE438737T1 (de)	2009-08-15	Verfahren für den nachweis von erkrankungen
ATE278186T1 (de)	2004-10-15	Elektrochemischer sensor zur bestimmung der blutgerinnung, ein entsprechendes blutgerinnungsmesssystem sowie ein verfahren zur bestimmung der blutgerinnung
DE60207979D1 (de)	2006-01-19	Verfahren und Vorrichtung zur Bestimmung der Gewebespezifität von freier DNA in Körperflüssigkeiten
DK505489A (da)	1990-04-14	Apparat og fremgangsmaade til indikering af tilboejelighed til dannelse af nyresten og til dehydrering, isaer hos mennesker
DE60315715D1 (de)	2007-09-27	Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60331857D1 (de)	2010-05-06	Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
DE60133510D1 (de)	2008-05-21	Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
ATE513851T1 (de)	2011-07-15	Menschliches gen zur fruchtbarkeit entscheidend
ATE408145T1 (de)	2008-09-15	Verfahren zum nachweis von nierenkrankheiten und zur pathologischen überwachung
DE602004020372D1 (de)	2009-05-14	Verfahren zur probenvorbehandlung sowie immunologisches testverfahren unter verwendung davon
ATE434760T1 (de)	2009-07-15	Blutzellen-detektor, blutanalysegerät und blutanalyseverfahren unter verwendung des detektors
DE69531505D1 (de)	2003-09-18	Verfahren zur zellerkennung
DE60225168D1 (de)	2008-04-03	Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür